SY-4835

Shouyao Holdings (Beijing) Co. LTD · Phase 1 active Small molecule

At a glance

Generic name	SY-4835
Also known as	SY-4835 tablets
Sponsor	Shouyao Holdings (Beijing) Co. LTD
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SY-4835 CI brief — competitive landscape report
SY-4835 updates RSS · CI watch RSS
Shouyao Holdings (Beijing) Co. LTD portfolio CI